Physician profile
Eli Lavie
NPI 1831116920
$10,809.02
in general payments reported to CMS, 2019-2025
30 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,662 · 2020: $1,183 · 2021: $1,076 · 2022: $1,486 · 2023: $1,995 · 2024: $2,184 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,401.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,402.67 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,399.43 | 2019-2025 | Xarelto, Opsumit, Uptravi |
| Novo Nordisk INC | $1,275.41 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $1,010.21 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $905.92 | 2019-2025 | Jardiance |
| Ge Healthcare | $642.00 | 2020 | |
| Medtronic, INC. | $576.55 | 2021-2025 | Linq II, Selectsecure, Corevalve Evolut R |
| E.R. Squibb & Sons, L.L.C. | $542.72 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $511.02 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $411.32 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Amgen INC. | $336.03 | 2019-2025 | Repatha |
| Boston Scientific Corporation | $235.77 | 2019-2025 | Watchman Flx, Watchman Access System |
| Impulse Dynamics (USA) INC. | $175.94 | 2023 | Optimizer |
| Edwards Lifesciences Corporation | $161.65 | 2022 | |
| Abbott Laboratories | $151.43 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $145.09 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $144.91 | 2023-2024 | Uptravi, Opsumit |
| Abiomed | $131.45 | 2024-2025 | Impella |
| Lexicon Pharmaceuticals, INC. | $121.14 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $112.00 | 2019 | |
| Amarin Pharma, INC. | $111.81 | 2019 | |
| Alnylam Pharmaceuticals INC. | $89.46 | 2025 | Onpattro |
| Bridgebio Pharma, INC. | $37.10 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $36.46 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $36.34 | 2023-2025 | Verquvo |
| Kiniksa Pharmaceuticals, Ltd. | $32.76 | 2022-2023 | Arcalyst |
| Esperion Therapeutics, INC. | $24.70 | 2022 | |
| Lantheus Medical Imaging, INC. | $18.02 | 2025 | |
| Chiesi USA, INC. | $15.00 | 2020 | |
| Lilly USA, LLC | $14.71 | 2024 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eli Lavie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.